Re: Drugdoctor;
I can see the potential for a good Q2, in part due to Fluticare sales. I could even believe Innovus might hit 4.5m in Q2.
I agree that Fluticare sales in will decrease in Q3 as the peak allergy season dissipates.
I'm sure that Q4, Fluticare, sales will drop to basically nothing, since the allergy season will be over and mostly, only, the less prevalent, in-door allergies would need to be treated.
If Innovus was selling Fluticare world-wide, then allergy season sales would always occur.
At this point, I think Innovus would be lucky, just to sell all of their 1st batch of 220,000 Fluticare units, which would actually include having had doctors give away free samples, as well as selling it for lowered prices/profits.
Yes, there are new-ish Innovus products ramping up closer to their full potential, such as Urivarx and Prostagorx.
The new diabetic products will take a while to ramp up, especially without any "good" advertising.
I could see where Innovus would have 9m in Q1+Q2 revs.
I don't count on another 9-10m in Q3+Q4.
In my opinion, there are no cinches here, like 1m in revs for 2018. 1m in revs for 2018 is not much, based on 19-20m in revs for 2018. Last year, Dr.D stated profitability could occur at between 10-15m.
Slowing down newspaper advertising would result in lower sales. Internet, radio and TV adverting are more effective than newspapers.
80% profits are not occuring with Fluticare, due to lowered prices. In general, I think Innovus products are priced to high.
It won't be easy to have net profits in 2018.
It might be a good idea to accumulate more throughout 2018 and hope for profitability at the end of 2019.
